Table 5

Results of CK-19 mRNA detection by nested RT-PCR for the 30 patients treated with trastuzumab and the 5 control patients

Patient numberTumor HER-2 statusHER-2 mRNA expression on pretreatment CK-19–positive sampleType of treatmentCK-19 mRNA Before treatment (BM/PB)CK-19 mRNA after treatment (BM/PB)Follow-up post-trastuzumab treatment (BM/PB)Duration of CK-19 mRNA negativity (mo)
4–6 wks8–9 wks3 mo6 mo9 mo12 mo15 mo18 mo21 mo
10+weekly+/−−/−−/−−/−−/−−/−−/−nd/+18
20+3-weeklynd/+nd/+nd/−nd/−nd/−nd/−9+
303-weeklynd/+nd/−+/−nd/+9
4+1+weekly+/−+/−0
50+weeklynd/+nd/−nd/+3
60+3-weeklynd/+nd/−nd/−nd/−nd/−9+
7+2ndcontrolnd/+nd/+
8+1+weekly+/++/−nd/+3
90+3-weeklynd/+nd/−nd/−nd/−nd/−9+
100+3-weeklynd/+nd/−nd/−−/−−/−9+
11+3+weekly+/−+/−−/−−/−−/−−/−−/−−/−−/−21+
12+3weekly+/−−/−−/−−/−−/−−/−12+
13+13-weekly+/−+/++/+0
140+3-weeklynd/+nd/+nd/−nd/−3+
15+3+weekly+/−+/−−/−−/−−/−+/+9
16+3+weekly+/−−/−−/−−/−−/−−/−+/+15
170+weekly+/+−/−−/−+/−3
18+2+weekly+/++/−−/−dead3
19+2+weekly+/−−/−−/−−/−−/−−/−+/+15
20+2+weekly+/+−/−+/+3
210+weekly+/−−/−−/−−/−−/−−/−−/−−/−15+
22+3+weekly−/+−/−−/−−/−−/−−/−+/−15
23+2+weekly+/+−/−−/−dead3
240weekly+/−−/−−/−−/−−/−−/−−/−15+
250+weekly+/−−/−−/−−/−dead6
26+1+weekly+/−−/−+/−3
270+weekly−/+−/−nd/+3
28UK+weekly+/−−/−+/−3
29+1+3-weekly+/−−/−−/−−/−−/−9+
3003-weeklynd/+nd/+nd/−nd/−nd/−6+
31+3+3-weekly+/+−/−−/−3+
32+3ndControlnd/+nd/+
330ndControlnd/+nd/+
34+1ndControlnd/+nd/+
35+1ndControlnd/+nd/+
  • Abbreviations: BM, bone marrow; PB, peripheral blood; nd, not done; UK, unknown.